Optimal tigecycline dosage regimen is urgently needed: Results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation

International Journal of Infectious Diseases

Volumn 18, Issue 1, 2014, Pages 62-67

  Xie, Jiao ^a   Wang, Taotao ^a   Sun, Jinyao ^a   Chen, Siying ^a   Cai, Jiangxia ^a   Zhang, Weipeng ^a   Dong, Haiyan ^a   Hu, Sasa ^a   Zhang, Di ^a   Wang, Xue ^a   Dong, Yalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Monte Carlo simulation; Optimal dosage regimen; Pharmacokinetic pharmacodynamic analysis; Tigecycline

Indexed keywords

TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SCREENING; ENTEROBACTER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; SKIN INFECTION; TREATMENT RESPONSE;

MONTE CARLO SIMULATION; OPTIMAL DOSAGE REGIMEN; PHARMACOKINETIC/PHARMACODYNAMIC ANALYSIS; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROBACTER; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MONTE CARLO METHOD;

EID: 84891560670     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.09.008     Document Type: Article

References (40)

1. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl 5):S354-S367.
2. Bradford P.A., Weaver-Sands D.T., Petersen P.J. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005, 41(Suppl 5):S315-S332.
3. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl 5):S341-S353.
4. Petersen P.J., Bradford P.A. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother 2005, 49:3910-3918.
5. Balode A., Punda-Polic V., Dowzicky M.J. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010. Int J Antimicrob Agents 2013, 41:527-535.
6. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance mechanism in India. Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
7. Rodríguez-Avial C., Rodríguez-Avial I., Merino P., Picazo J. Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient. Clin Microbiol Infect 2012, 18:61-66.
8. Neonakis I.K., Stylianou K., Daphnis E., Maraki S. First case of resistance to tigecycline by Klebsiella pneumoniae in a European University Hospital. Indian J Med Microbiol 2011, 29:78-79.
9. Al-Qadheeb N.S., Althawadi S., Alkhalaf A., Hosaini S., Alrajhi A.A. Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient. Ann Saudi Med 2010, 30:404-407.
10. Hornsey M., Loman N., Wareham D.W., Ellington M.J., Pallen M.J., Turton J.F., et al. Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother 2011, 66:1499-1503.
11. Chen L.Y., Chen T.C., Chen Y.H., Lin C.Y., Lin W.R., Lu P.L. Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage. J Microbiol Immunol 2011, 44:352-357.
12. Kopterides P., Papageorgiou C., Antoniadou A., Papadomichelakis E., Tsangaris I., Dimopoulou I., et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010, 38:755-758.
13. Gallagher J.C., Rouse H.M. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 2008, 42:1188-1194.
14. Reid G.E., Grim S.A., Aldeza C.A., Janda W.M., Clark N.M. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007, 27:1198-1201.
15. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007, 59:128-131.
16. Anthony K.B., Fishman N.O., Linkin D.R., Gasink L.B., Edelstein P.H., Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008, 46:567-570.
17. Daurel C., Fiant A.L., Bremont S., Courvalin P., Leclercq R. Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy. Antimicrob Agents Chemother 2009, 53:4953-4954.
18. Sherwood J.E., Fraser S., Citron D.M., Wexler H., Blakely G., Jobling K., et al. Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. Anaerobe 2011, 17:152-155.
19. Postier R.G., Green S.L., Klein S.R., Ellis-Grosse E.J., Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004, 26:704-714.
20. Koomanachai P., Kim A., Nicolau D.P. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J Antimicrob Chemother 2009, 63:982-987.
21. Meagher A.K., Ambrose P.G., Grasela T.H., Grosse J.E. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005, 41:S333-S340.
22. Mouton J.W., Dudley M.N., Cars O., Derendorf H., Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005, 55:601-607.
23. Canut A., Isla A., Betriu C., Gascón A. Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four Western European countries. Eur J Clin Microbiol 2012, 31:2227-2235.
24. Muralidharan G., Micalizzi M., Speth J., Raible D., Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005, 49:220-229.
25. Meagher A.K., Passarell J.A., Cirincione B.B., Van Wart S.A., Liolios K., Babinchak T., et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007, 51:1939-1945.
26. Passarell J.A., Meagher A.K., Liolios K., Cirincione B.B., Van Wart S.A., Babinchak T., et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008, 52:204-210.
27. Kahlmeter G., Brown D., Canton R., MacGowan A., Mouton J., Rodloff A. EUCAST technical note on tigecycline. Clin Microbiol Infect 2006, 12:1147-1149.
28. Bonate P.L. A brief introduction to Monte Carlo simulation. Clin Pharmacokinet 2001, 40:15-22.
29. Mouton J.W., Schmitt-Hoffmann A., Shapiro S., Nashed N., Punt N.C. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 2004, 48:1713-1718.
30. De'ath G., Fabricius K.E. Classification and regression trees: a powerful yet simple technique for ecological data analysis. Ecology 2000, 81:3178-3192.
31. Alişkan H., Can F., Demirbilek M., Çolakoglu Ş., Kilic S., Arslan H. Determining in vitro synergistic activities of tigecycline with several other antibiotics against Brucella melitensis using checkerboard and time-kill assays. J Chemother 2009, 21:24-30.
32. Dizbay M., Tozlu D.K., Cirak M.Y., Isik Y., Ozdemir K., Arman D. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J Antibiot (Tokyo) 2009, 63:51-53.
33. Entenza J., Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009, 34:8. e1-e9.
34. Consales G., Gramigni E., Zamidei L., Bettocchi D., De Gaudio A.R. A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: antimicrobial and organizational strategies. J Crit Care 2011, 26:453-459.
35. Shin J.A., Chang Y.S., Kim H.J., Kim S.K., Chang J., Ahn C.M., et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei Med J 2012, 53:974-984.
36. Gordon N., Wareham D. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009, 63:775-780.
37. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008, 62:895-904.
38. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008, 62:45-55.
39. Ambrose P.G., Bhavnani S.M., Grosse E.J., Drusano G.L. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!. Clin Infect Dis 2010, 51:S103-S110.
40. Burkhardt O., Rauch K., Kaever V., Hadem J., Kielstein J.T., Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009, 34:101-102.